| Company Name: | Omnicare, Incorporated | | Ticker Symbol: | OCR | | | WWW Address: | www.omnicare.com | | CEO: | Joel F. Gemunder | | No. of Employees: | 15,400 | | Common Issue Type: | CS | | Business Description: | A geriatric pharmaceutical services company, which provides pharmaceuticals and related pharmacy and ancillary services to long-term healthcare institutions.
|
| | | Industry Information: | WHOLESALE - Drugs Wholesale [more like this] |
|
| Price | Day Change | Bid | Ask | Open | High | Low | Volume | | 23.47 |  -0.2 | 22.57 | 24.25 | 23.6 | 23.74 | 23.44 | 713302 |
| Market Cap (mil) | Shares Outstanding (mil) | Beta | EPS | DPS | P/E | Yield | 52-Wks-Range |
| 2,800.0 | 119.3 | 0.49 | 1.32 | 0.09 | 16.8 | 0.4 | 29.74 - 20.55 |
|
| KEY FIGURES (Latest Twelve Months - LTM) | | Yesterday's Close | 23.47 | $ | | PE Ratio - LTM | 16.8 | |
| Market Capitalisation | 2,800.8 | mil |
| Latest Shares Outstanding | 119.3 | mil |
| Earnings pS (EPS) | 1.32 | $ |
| Dividend pS (DPS) | 0.09 | ¢ |
| Dividend Yield | 0.4 | % |
| Dividend Payout Ratio | 7 | % |
| Revenue per Employee | 409,780 | $ |
| Effective Tax Rate | 40.0 | % |
| Float | 115.8 | mil |
| Float as % of Shares Outstanding | 97.0 | % |
| Foreign Sales | 72 | mil |
| Domestic Sales | 6,238 | mil |
| Selling, General & Adm/tive (SG&A) as % of Revenue | 18.30 | % |
| Research & Devlopment (R&D) as % of Revenue | 0.00 | % |
| Gross Profit Margin | 27.0 | % |
| EBITDA Margin | 8.7 | % |
| Pre-Tax Profit Margin | 4.6 | % |
| Assets Turnover | 0.8 | % |
| Return on Assets (ROA) | 2.2 | % |
| Return on Equity (ROE) | 4.3 | % |
| Return on Capital Invested (ROCI) | 2.8 | % |
| Current Ratio | 3.0 | |
| Leverage Ratio (Assets/Equity) | 1.9 | |
| Interest Cover | 3.3 | |
| Total Debt/Equity (Gearing Ratio) | 0.56 | |
| LT Debt/Total Capital | 34.0 | % |
| Working Capital pS | 12.74 | $ |
| Cash pS | 2.72 | $ |
| Book-Value pS | 31.94 | $ |
| Tangible Book-Value pS | -6.20 | $ |
| Cash Flow pS | 2.50 | $ |
| Free Cash Flow pS | 3.33 | $ |
 |
| KEY FIGURES (LTM): Price info |
| Price/Book Ratio | 0.73 | |
| Price/Tangible Book Ratio | -3.78 | |
| Price/Cash Flow | 9.4 | |
| Price/Free Cash Flow | 7.0 | |
| P/E as % of Industry Group | 42.0 | % |
| P/E as % of Sector Segment | 91.0 | % |
| | | Balance Sheet (at a glance) in Millions |
| | | | | | DIVIDEND INFO | | Dividend Declared Date | 08/10/2009 |
| Dividend Ex-Date | 08/25/2009 |
| Dividend Record Date | 08/27/2009 |
| Dividend Pay Date | 09/13/2009 |
| Dividend Amount | 22 |
| Type of Payment | Cash Payment |
| Dividend Rate | 0.09 |
| Current Dividend Yield | 0.4 |
| 5-Y Average Dividend Yield | 0.2 |
| Payout Ratio | 7.0 |
| 5-Y Average Payout Ratio | 6.0 |
|  | | Share price performance previous 3 years |
|
 | | | Share price performance intraday |
|
 | |
| |
| PRICE/VOLUME | High | Low | Close | % Price Chg | % Price Chg vs. Mkt. | Avg. Daily Vol | Total Vol |
| 1 Week | - | - | - | 0.9 | 100 | 10,627 | 13,531 |
| 4 Weeks | 24.58 | 21.50 | 21.67 | 8.3 | 101 | 14,100 | 239,692 |
| 13 Weeks | 24.64 | 21.26 | 23.00 | 2.0 | 95 | 13,732 | 837,626 |
| 26 Weeks | 27.98 | 20.55 | 27.03 | -13.2 | 72 | 14,894 | 1,861,750 |
| 52 Weeks | 29.74 | 20.55 | 24.11 | -2.7 | 79 | 15,689 | 3,906,566 |
| YTD | 29.74 | 20.55 | - | -15.5 | 69 | 16,038 | 3,640,688 |
| Moving Average | 5-Days | 10-Days | 10-Weeks | 30-Weeks | 200-Days | Beta (60-Mnth) | Beta (36-Mnth) |
| 23.63 | 23.87 | 22.70 | 24.21 | 24.57 | 0.49 | 0.36 |
|
| |
| GROWTH RATES | 5-Year
Growh | R² of 5-Year Growth | 3-Year
Growth |
| Revenue | 8.55 | 67.3 | -1.09 |
| Income | -11.72 | 54.6 | -0.25 |
| Dividend | 0.00 | 0.0 | 0.00 |
| Capital Spending | -24.04 | NA | -46.30 |
| R&D | 0.00 | NA | 0.00 |
| Normalized Inc. | -10.28 | NA | -17.99 |
| | | CHANGES | YTD vs.
Last YTD | Curr Qtr vs.
Qtr 1-Yr ago | Annual vs.
Last Annual |
| Revenue % | -1.8 | -3.7 | 1.5 |
| Earnings % | 6.2 | 25.7 | 36.9 |
| EPS % | 6.7 | 26.5 | 40.4 |
| EPS $ | 0.07 | 0.13 | 0.38 |
|
| |
| SOLVENCY RATIOS | | SHORT-TERM SOLVENCY RATIOS (LIQUIDITY) |
| Net Working Capital Ratio | 23.20 |
| Current Ratio | 3.7 |
| Quick Ratio (Acid Test) | 2.5 |
| Liquidity Ratio (Cash) | 0.34 |
| Receivables Turnover | 4.5 |
| Average Collection Period | 80 |
| Working Capital/Equity | 50.6 |
| Working Capital pS | 14.61 |
| Cash-Flow pS | 2.31 |
| Free Cash-Flow pS | 1.19 |
| FINANCIAL STRUCTURE RATIOS |
| Altman's Z-Score Ratio | 1.70 |
| Financial Leverage Ratio (Assets/Equity) | 2.2 |
| Debt Ratio | 54.1 |
| Total Debt/Equity (Gearing Ratio) | 0.80 |
| LT Debt/Equity | 0.80 |
| LT Debt/Capital Invested | 55.2 |
| LT Debt/Total Liabilities | 67.6 |
| Interest Cover | 2.8 |
| Interest/Capital Invested | 2.11 |
| | | | VALUATION RATIOS | | MULTIPLES |
| PQ Ratio | 5.22 |
| Tobin's Q Ratio | 0.38 |
| Current P/E Ratio - LTM | 16.80 |
| Enterprise Value (EV)/EBITDA | 12.07 |
| Enterprise Value (EV)/Free Cash Flow | 63.25 |
| Dividend Yield | 0.4 |
| Price/Tangible Book Ratio - LTM | -3.78 |
| Price/Book Ratio - LTM | 0.73 |
| Price/Cash Flow Ratio | 9.4 |
| Price/Free Cash Flow Ratio - LTM | 7.0 |
| Price/Sales Ratio | 0.45 |
| P/E Ratio (1 month ago) - LTM | 16.3 |
| P/E Ratio (26 weeks ago) - LTM | 20.3 |
| P/E Ratio (52 weeks ago) - LTM | 27.4 |
| 5-Y High P/E Ratio | 47.7 |
| 5-Y Low P/E Ratio | 11.5 |
| 5-Y Average P/E Ratio | 22.9 |
| Current P/E Ratio as % of 5-Y Average P/E | 73 |
| P/E as % of Industry Group | 42.0 |
| P/E as % of Sector Segment | 91.0 |
| Current 12 Month Normalized P/E Ratio - LTM | 17.1 |
| PER SHARE FIGURES |
| LT Debt pS | 23.05 |
| Current Liabilities pS | 5.41 |
| Tangible Book Value pS - LTM | -6.20 |
| Book Value pS - LTM | 31.94 |
| Capital Invested pS | 51.56 |
| Cash pS - LTM | 2.72 |
| Cash Flow pS - LTM | 2.50 |
| Free Cash Flow pS - LTM | 3.33 |
| Earnings pS (EPS) | 1.32 |
| | | | OPERATING RATIOS | | PROFITABILITY RATIOS |
| Free Cash Flow Margin | 2.23 |
| Free Cash Flow Margin 5YEAR AVG | -8.96 |
| Net Profit Margin | 2.5 |
| Net Profit Margin - 5YEAR AVRG. | 3.2 |
| Equity Productivity | 1.84 |
| Return on Equity (ROE) | 4.6 |
| Return on Equity (ROE) - 5YEAR AVRG. | 6.2 |
| Capital Invested Productivity | 1.03 |
| Return on Capital Invested (ROCI) | 2.5 |
| Return on Capital Invested (ROCI) - 5YEAR AVRG. | 3.4 |
| Assets Productivity | 0.80 |
| Return on Assets (ROA) | 2.1 |
| Return on Assets (ROA) - 5YEAR AVRG. | 2.7 |
| Gross Profit Margin | 27.0 |
| Gross Profit Margin - 5YEAR AVRG. | 26.7 |
| EBITDA Margin - LTM | 8.7 |
| EBIT Margin - LTM | 6.6 |
| Pre-Tax Profit Margin | 4.1 |
| Pre-Tax Profit Margin - 5YEAR AVRG. | 5.3 |
| Effective Tax Rate | 40.0 |
| Effective Tax Rate - 5YEAR AVRG. | 39.2 |
| EFFICIENCY RATIOS |
| Cash Conversion Cycle | 114 |
| Revenue per Employee | 409,780 |
| Net Income per Employee | 10,137 |
| Average Collection Period | 79 |
| Receivables Turnover | 4.5 |
| Day's Inventory Turnover Ratio | 35 |
| Inventory Turnover | 10.2 |
| Inventory/Sales | 7.2 |
| Accounts Payble/Sales | 5.38 |
| Assets/Revenue | 1.25 |
| Net Working Capital Turnover | 3.65 |
| Fixed Assets Turnover | 1.24 |
| Total Assets Turnover | 0.8 |
| Revenue per $ Cash | 29.34 |
| Revenue per $ Plant | 28.73 |
| Revenue per $ Common Equity | 1.84 |
| Revenue per $ Capital Invested | 1.03 |
| Selling, General & Adm/tive (SG&A) as % of Revenue | 18.4 |
| SG&A Expense as % of Revenue - 5YEAR AVRG. | 16.2 |
| Research & Devlopment (R&D) as % of Revenue | 0.0 |
| R&D Expense as % of Revenue - 5YEAR AVRG. | 0.0 |
|
|  
|
| |
 |  |